Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659563 | 0.94 | ITGB3 (0.31) | ITGB3ITGA2BPDE3BPDE3APOLB | |
| SCHEMBL13348412 | 0.93 | ITGB3 (0.32) | ITGB3ITGA2BITGAV | |
| SCHEMBL13221657 | 0.92 | SYK (0.32) | ITGB3ITGA2BFAAHITGAV | |
| SCHEMBL13222229 | 0.92 | ITGB3 (0.32) | ITGB3ITGA2BITGAV | |
| SCHEMBL13312856 | 0.92 | ITGB3 (0.30) | ITGB3ITGA2BDRD2DRD3 | |
| SCHEMBL13221707 | 0.88 | ITGB3 (0.33) | ITGB3ITGA2BNAMPTPDE3BPDE3A | |
| SCHEMBL2659494 | 0.87 | ITGB3 (0.32) | ITGB3ITGA2BPDE3BPDE3AITGAV | |
| SCHEMBL2659939 | 0.87 | ITGB3 (0.32) | ITGB3ITGA2BITGAV | |
| SCHEMBL2659399 | 0.86 | SYK (0.32) | ITGB3ITGA2BITGAV | |
| SCHEMBL2660036 | 0.86 | ITGB3 (0.32) | ITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144702-A1 | INDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | US | disclosed |
| US-20100137610-A1 | Indole compound | YASUMA TSUNEO | 2010-06-03 | — | — | US | disclosed |
| US-7718798-B2 | Indole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20090286975-A1 | Indole compound | YASUMA TSUNEO | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144702-A1 | INDOLE COMPOUND | GCKR, GPR119, SLC5A1 | ITGB3 4797/4885ITGA2B 4779/4885NAMPT 580/4885 |
| US-20100137610-A1 | Indole compound | GCKR, GPR119, SLC5A1 | ITGB3 4797/4885ITGA2B 4779/4885NAMPT 580/4885 |
| US-20090286975-A1 | Indole compound | GCKR, GPR119, SLC5A1 | ITGB3 4797/4885ITGA2B 4779/4885NAMPT 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.